Clinical Trial Update: Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AVP-786 for agitation in Alzheimer's disease dementia has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | Status: TERMINATED | Results posted: 2025-05-30